Business Wire1mon
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...
Hosted on MSN11mon
Vertex Pharmaceuticals' Triple Combo Treatment For Lung Disorder Meets Primary Goal In Adult And Pediatric Patients
Vertex Pharmaceuticals Incorporated (NASDAQ ... evaluating vanzacaftor (20 mg)/tezacaftor (100 mg)/deutivacaftor (250 mg) in patients aged 12 and above, compared to Trikafta (elexacaftor ...